Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: harsh (4), strict (49), acute (409)

Papers Trust Board - 11 March 2025

Description: Date Time Location Chair Agenda Trust Board – Open Session 11/03/2025 9:00 - 13:00 Conference Room, Heartbeat Education Centre
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2025-Trust-documents/Papers-Trust-Board-11-March-2025.pdf

Tarlatamab (EAMS)

Description: Chemotherapy Protocol LUNG CANCER – SMALL CELL (SCLC) Tarlatamab (EAMS) Regimen • SCLC – Tarlatamab (EAMS) Indication • Tarlatamab is indicated as mon
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-small-cellSCLC/Tarlatamab-EAMS-Ver-1.0.pdf

Carboplatin-Docetaxel-Pertuzumab-Trastuzumab_IV-SC

Description: Chemotherapy Protocol BREAST CANCER CARBOPLATIN (AUC6)-DOCETAXEL- PERTUZUMABTRASTUZUMAB (IV/SC) Regimen • Breast Cancer – Carboplatin (AUC6)-Do
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Carboplatin-Docetaxel-Pertuzumab-Trastuzumab-IV-SC.pdf

EC-DPH IV (Cyclophosphamide-Epirubicin-Docetaxel-Pertuzumab-Trastuzumab IV)

Description: Please refer to the most up to date Bluteq eligibility criteria for pertuzumab and trastuzumab before prescribing.
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/EC-DPH-IV-Cyclophosphamide-Epirubicin-Docetaxel-Pertuzumab-Trastuzumab-IV.pdf

Carboplatin-Docetaxel-Pertuzumab-Trastuzumab_IV

Description: Chemotherapy Protocol BREAST CANCER CARBOPLATIN (AUC 6)-DOCETAXEL-PERTUZUMABTRASTUZUMAB (IV) Regimen • Breast Cancer – Carboplatin (AUC6)-Docet
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Carboplatin-Docetaxel-Pertuzumab-Trastuzumab-IV.pdf

22q11 deletion (DiGeorge syndrome) - patient information

Description: This factsheet explains what 22q11 deletion (also known as DiGeorge syndrome) is, what the common symptoms of the condition are and
Url: /Media/UHS-website-2019/Patientinformation/Childhealth/22q11-deletion-DiGeorge-syndrome-3121-PIL.pdf

BV-CHP Brentuximab vedotin-cyclophosphamide-doxorubicin-prednisolone Ver1

Description: Chemotherapy Protocol LYMPHOMA BRENTUXIMAB VEDOTIN-CYCLOPHOSPHAMIDE-DOXORUBICIN-PREDNISOLONE (BV-CHP) Regimen • Lymphoma – Brentuximab vedotin-cyclophosphamide-doxorubicin-prednis
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/BV-CHP-Brentuximab-vedotin-cyclophosphamide-doxorubicin-prednisolone.pdf

mini-RCHOP 21

Description: Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-DOXORUBICIN-PREDNISOLONE-RITUXIMAB-VINCRISTINE (mini-RCHOP 21) Regimen   Lymphoma – mini-RCHOP (21)-Cyclophosphamide-Doxorubicin-PrednisoloneRituximab-Vinc
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/mini-RCHOP-21.pdf

Cytarabine(SC)-Venetoclax

Description: Chemotherapy Protocol Acute Myeloid Leukaemia CYTARABINE (SC) - VENETOCLAX Regimen  AML – Cytarabine (SC) -Venetoclax Indication  Newl
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/AML/CytarabineSC-Venetoclax.pdf

Dihydropyrimidine dehydrogenase (DPD) testing (dihydropyrimidine dehydrogenase) - patient information

Description: This factsheet explains what DPD testing is and why your doctor has recommended it for you.
Url: /Media/UHS-website-2019/Patientinformation/Cancercare/Dihydropyrimidine-dehydrogenase-DPD-testing-dihydropyrimidine-dehydrogenase-3172-PIL.pdf

231 to 240 of 726

Previous … 22 23 24 25 26 … Next